-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VE-303 in Clostridioides difficile Infections (Clostridium difficile Associated Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VE-303 in Clostridioides difficile Infections (Clostridium difficile Associated Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VE-303 in Clostridioides difficile Infections (Clostridium difficile...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plonmarlimab in Hemophagocytic Lymphohistiocytosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Plonmarlimab in Hemophagocytic Lymphohistiocytosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plonmarlimab in Hemophagocytic Lymphohistiocytosis Drug Details: Plonmarlimab (TJM-2) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KITE-363 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KITE-363 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KITE-363 in Diffuse Large B-Cell Lymphoma Drug Details: KITE-363 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TTX-030 in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TTX-030 in Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TTX-030 in Lymphoma Drug Details: TTX-030 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TTX-030 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TTX-030 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TTX-030 in Pancreatic Ductal Adenocarcinoma Drug Details: TTX-030 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TTX-030 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TTX-030 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TTX-030 in Solid Tumor Drug Details: TTX-030 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TTX-030 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TTX-030 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TTX-030 in Gastric Cancer Drug Details:TTX-030 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TTX-030
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry TTX-030 Drug Details TTX-030 is under development for the treatment of solid tumors like...
-
Product Insights
Gastric Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Gastric Cancer signs and symptoms include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Treatment includes surgery, chemotherapy, and radiation therapy. The Gastric Cancer pipeline drugs market research report provides an analysis of the Gastric Cancer drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and...
-
Product Insights
Pancreatic Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer – Drugs In Development, 2022, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood...